Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up.

Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest (2005) 4.25

Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 3.56

Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest (2010) 3.09

Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull (2011) 2.26

Stem cell paracrine actions and tissue regeneration. Regen Med (2010) 1.99

Stem cell therapy is proarrhythmic. Circulation (2009) 1.83

Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J (2011) 1.80

Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol (2012) 1.60

Myocardial infarction and intramyocardial injection models in swine. Nat Protoc (2012) 1.47

Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation. J Clin Invest (2004) 1.38

Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31

Electrophysiological challenges of cell-based myocardial repair. Circulation (2009) 1.30

Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J Cardiovasc Transl Res (2010) 1.28

X-ray fused with magnetic resonance imaging (XFM) to target endomyocardial injections: validation in a swine model of myocardial infarction. Circulation (2006) 1.23

Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies. Heart Rhythm (2008) 1.19

Stem cell therapy: MRI guidance and monitoring. J Magn Reson Imaging (2008) 1.17

Adult stem cells and their trans-differentiation potential--perspectives and therapeutic applications. J Mol Med (Berl) (2008) 1.12

Bone marrow mononuclear stem cells transplanted in rat infarct myocardium improved the electrical conduction without evidence of proarrhythmic effects. Yonsei Med J (2007) 1.05

Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv (2012) 1.03

Cell therapy for cardiovascular disease: a comparison of methods of delivery. J Cardiovasc Transl Res (2010) 1.03

Current perspectives on imaging cardiac stem cell therapy. J Nucl Med (2010) 1.00

Stem cells for heart cell therapies. Tissue Eng Part B Rev (2008) 0.98

Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat. PLoS One (2008) 0.97

Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. J Cell Mol Med (2007) 0.97

High-resolution magnetic resonance imaging of iron-labeled myoblasts using a standard 1.5-T clinical scanner. MAGMA (2004) 0.96

Skeletal myoblasts for cardiac repair. Regen Med (2010) 0.95

Cell delivery and tracking in post-myocardial infarction cardiac stem cell therapy: an introduction for clinical researchers. Heart Fail Rev (2010) 0.93

Regenerating functional heart tissue for myocardial repair. Cell Mol Life Sci (2012) 0.92

Tracking of stem cells in vivo for cardiovascular applications. J Cardiovasc Magn Reson (2014) 0.92

Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol Pharm (2011) 0.91

Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications. Curr Cardiol Rev (2011) 0.91

Current stem cell delivery methods for myocardial repair. Biomed Res Int (2012) 0.89

c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. Clin Transl Sci (2009) 0.89

Catheter based simultaneous mapping of cardiac activation and motion: a review. Indian Pacing Electrophysiol J (2007) 0.88

Stem cell therapy for myocardial repair: is it arrhythmogenic? J Am Coll Cardiol (2003) 0.88

MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther (2008) 0.88

Calcium signalling of human pluripotent stem cell-derived cardiomyocytes. J Physiol (2013) 0.87

Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med (2009) 0.87

MiR-155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPCs) via targeting of MMP-16. J Cell Mol Med (2012) 0.86

Cardiac regeneration using pluripotent stem cells--progression to large animal models. Stem Cell Res (2014) 0.86

MRI-3D ultrasound-X-ray image fusion with electromagnetic tracking for transendocardial therapeutic injections: in-vitro validation and in-vivo feasibility. Comput Med Imaging Graph (2013) 0.86

Intracoronary infusion of mononuclear cells after PCI-treated myocardial infarction and arrhythmogenesis: is it safe? Neth Heart J (2012) 0.86

Cardiac repair by embryonic stem-derived cells. Handb Exp Pharmacol (2006) 0.85

Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome? EPMA J (2011) 0.85

Congestive heart failure in Indians: how do we improve diagnosis & management? Indian J Med Res (2010) 0.84

Cell transplantation for cardiac regeneration: where do we stand? Neth Heart J (2008) 0.84

Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res (2014) 0.84

More Than Tiny Sacks: Stem Cell Exosomes as Cell-Free Modality for Cardiac Repair. Circ Res (2016) 0.84

Overexpression of connexin 43 using a retroviral vector improves electrical coupling of skeletal myoblasts with cardiac myocytes in vitro. BMC Cardiovasc Disord (2006) 0.84

Myocardial regeneration of the failing heart. Heart Fail Rev (2013) 0.81

Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques. Imaging Med (2011) 0.81

Autologous cardiomyotissue implantation promotes myocardial regeneration, decreases infarct size, and improves left ventricular function. Circulation (2010) 0.80

Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentation. Tex Heart Inst J (2005) 0.79

Cell and gene therapy for arrhythmias: Repair of cardiac conduction damage. J Geriatr Cardiol (2011) 0.79

Increased angiogenesis and improved left ventricular function after transplantation of myoblasts lacking the MyoD gene into infarcted myocardium. PLoS One (2012) 0.78

Gene and cell therapy for heart failure. Antioxid Redox Signal (2009) 0.77

Therapeutic potential of Pnmt+ primer cells for neuro/myocardial regeneration. Am J Stem Cells (2013) 0.77

Heart failure management: the present and the future. Antioxid Redox Signal (2009) 0.77

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology. Br J Pharmacol (2013) 0.76

Cellular replacement therapy for arrhythmia treatment: early clinical experience. J Interv Card Electrophysiol (2008) 0.76

Nuclear imaging in cardiac cell therapy. Heart Fail Rev (2006) 0.76

Validation of QwikStar Catheter for left ventricular electromechanical mapping with NOGA XP system. Tex Heart Inst J (2008) 0.76

Electrical effects of stem cell transplantation for ischaemic cardiomyopathy: friend or foe? J Physiol (2016) 0.76

Stem cells: An overview with respect to cardiovascular and renal disease. J Nat Sci Biol Med (2010) 0.76

Arrhythmia in stem cell transplantation. Card Electrophysiol Clin (2015) 0.76

Novel surface-enhanced Raman scattering-based assays for ultra-sensitive detection of human pluripotent stem cells. Biomaterials (2016) 0.75

Delivery and tracking of therapeutic cell preparations for clinical cardiovascular applications. Cytotherapy (2004) 0.75

New model for cardiomyocyte sheet transplantation using a virus-cell fusion technique. World J Stem Cells (2015) 0.75

Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion. Sci Rep (2016) 0.75

Cardiac repair--fact or fancy? Heart Fail Rev (2006) 0.75

Cellular cardiomyoplasty and cardiac regeneration. Curr Cardiol Rev (2008) 0.75

Validation of transcatheter left ventricular electromechanical mapping for assessment of cardiac function and targeted transendocardial injection in a porcine ischemia-reperfusion model. Am J Transl Res (2012) 0.75

Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering. J Stem Cell Transplant Biol (2015) 0.75

Understanding the application of stem cell therapy in cardiovascular diseases. Stem Cells Cloning (2012) 0.75

Comparison of arrhythmogenicity and proinflammatory activity induced by intramyocardial or epicardial myoblast sheet delivery in a rat model of ischemic heart failure. PLoS One (2015) 0.75

Intramyocardial cell delivery: observations in murine hearts. J Vis Exp (2014) 0.75

De novo myocardial regeneration: advances and pitfalls. Antioxid Redox Signal (2010) 0.75

Evaluation of global left ventricular function assessment of non-fluorescent electromechanical endocardial mapping compared with biplane left ventricular contrast angiography. Neth Heart J (2010) 0.75

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94

Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med (2009) 5.26

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16

Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA (2003) 5.10

High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J (2011) 4.47

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94

Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93

Acute myocardial infarction. Lancet (2003) 3.59

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (2013) 3.41

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29

Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12

Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06

Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91

Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90

Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation (2013) 2.88

Stent thrombosis. J Am Coll Cardiol (2010) 2.86

Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol (2008) 2.81

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet (2011) 2.67

Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med (2011) 2.65

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet (2008) 2.57

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54

Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50

Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43

Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation (2010) 2.40

Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36

Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32

Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2003) 2.31

Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30

Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24

Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J (2008) 2.22

Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20

Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr (2008) 2.19

Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation (2011) 2.17

Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17

Pro: Beta-blockers are indicated for patients at risk for cardiac complications undergoing noncardiac surgery. Anesth Analg (2007) 2.16

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14

Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv (2004) 2.12

Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

The obesity paradox in patients with peripheral arterial disease. Chest (2008) 2.09

Characterizing vulnerable plaque features with intravascular elastography. Circulation (2003) 2.07

Postoperative mortality in The Netherlands: a population-based analysis of surgery-specific risk in adults. Anesthesiology (2010) 2.04

Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv (2004) 2.04

Depression is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: results from the RESEARCH registry. Int J Cardiol (2012) 2.04

Coronary stents: current status. J Am Coll Cardiol (2010) 2.01

Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol (2005) 2.00

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99

Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation (2005) 1.98

Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation (2010) 1.96

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94

Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv (2012) 1.89

Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation (2006) 1.89

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens (2006) 1.88

Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology (2011) 1.87

Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial. Eur Heart J (2013) 1.87

Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation (2008) 1.87

Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam Study. Am Heart J (2010) 1.87

Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation (2004) 1.86

In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol (2005) 1.85

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J (2012) 1.85

Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84

Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis (2011) 1.84

Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. J Am Coll Cardiol (2004) 1.84

Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med (2004) 1.82

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet (2012) 1.80

Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol (2012) 1.80

Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention (2008) 1.80

Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 1.80

Determination of interobserver variability for identifying inducible left ventricular wall motion abnormalities during dobutamine stress magnetic resonance imaging. Eur Heart J (2006) 1.79

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J (2009) 1.79

Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J (2014) 1.78

The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol (2002) 1.78

Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2007) 1.77

Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg (2011) 1.77

Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging (2012) 1.77

Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol (2013) 1.76

Mitral valve repair and replacement in endocarditis: a systematic review of literature. Ann Thorac Surg (2007) 1.75

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation (2010) 1.75

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg (2012) 1.74

Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J (2005) 1.74

Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. Am Heart J (2004) 1.74

An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv (2010) 1.73

Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol (2008) 1.73

Quantitative ex vivo and in vivo comparison of lumen dimensions measured by optical coherence tomography and intravascular ultrasound in human coronary arteries. Rev Esp Cardiol (2009) 1.72